Here are the latest G-BA decisions from the G-BA meeting held on 19 March 2026 on the early benefit assessments of Enhertu, Ezmekly, Tevimbra, Lynozyfic, Taltz, Rybrevant, Alhemo, Idefirix, and Ronapreve.
A database of all previous G-BA resolutions is available in my store.
- Enhertu (Trastuzumab deruxtecan); reassessment based on new scientific evidence: Adenocarcinoma of the stomach or gastroesophageal junction, HER2+, after trastuzumab-based therapy – Indication of minor additional benefit
- Ezmekly (mirdametinib); neurofibromatosis type 1 (NF1)) ≥ 2 years – Orphan drug, Hint of not-quantifiable additional benefit
- Tevimbra (tislelizumab); new indication:
- Small cell lung cancer, first-line, in combination with etoposide and platinum chemotherapy – Additional benefit not proven
- Recurrent or metastatic nasopharyngeal cancer (NPC), first-line, in combination with gemcitabine and cisplatin – Additional benefit not proven
- Non-small cell lung cancer, high risk of recurrence, neoadjuvant and adjuvant therapy, monotherapy or in combination with platinum-based chemotherapy – Additional benefit not proven
- Lynozyfic (linvoseltamab); multiple myeloma, at least 3 prior therapies, monotherapy – Additional benefit not proven in both subgroups
- Taltz (ixekizumab); new indication:
- enthesitis-associated arthritis, ≥ 6 years – Additional benefit not proven
- juvenile psoriatic arthritis, ≥ 6 years – Additional benefit not proven
- Rybrevant (amivantamab); new indication: non-small cell lung cancer, EGFR exon 20 insertion mutation, first-line, in combination with carboplatin and pemetrexed – Time restriction of resolution was extended to 1 April 2027
- Alhemo (concizumab); new indication:
- haemophilia A, ≥ 12 years, without factor VIII inhibitors – Additional benefit not proven
- haemophilia B, ≥ 12 years, without factor IX inhibitors – Additional benefit not proven
- Idefirix (imlifidase); desensitization in kidney transplantation) – Time restriction of resolution was extended to 15 October 2026
- Ronapreve (casirivimab/imdevimab); post-exposure prophylaxis for COVID-19 infection, ≥ 12 years; COVID-19, ≥ 12 years – Repeal of resolution from 6 October 2022